- Hunter's Health Hacks
- Posts
- New Metformin Studies Out
Happy Monday!
Every year, a new “miracle supplement” tries to make its way onto the anti-aging stage.
But when the dust settles, one compound keeps shining brighter than the rest: Metformin.
It’s not new, it’s not sexy, but it keeps delivering.
And the latest 2025 research just turbocharged its case as the ultimate longevity molecule.
Whether you’re optimizing blood sugar, aiming for legendary healthspan, or stacking the deck against age-related diseases, it’s impossible to ignore what’s coming out of the world’s best research labs right now.
Let’s break down the latest science, piece by piece, so you can see why Metformin is still the gold standard in the biohacking playbook.
PSA: We have several other products on sale at BLL this until midnight PST. Use code HUNTERW to take an additional 15% off the products that are already discounted 20% for 35% off total.
1. Metformin, Women, and Longevity: A 30% Boost to Your Odds of Reaching 90
2025 brought us one of the most eye-opening longevity studies yet.
Published in the Journal of Gerontology: Medical Sciences, researchers used target trial emulation on data from the Women’s Health Initiative. The results?
Women with type 2 diabetes who started Metformin (instead of a sulfonylurea) had a 30% lower risk of dying before age 90.
The statistical breakdown: Hazard Ratio (HR) 0.70, meaning a robust effect in a real-world setting.
This is the first time we’ve seen this magnitude of survival benefit in such a large, diverse group of women.
The implication: If you’re a woman with diabetes, or just looking at metformin through an anti-aging lens, this is one of the most compelling arguments for keeping it in your daily stack.
2. Kidney Health: Is Metformin Safe in Advanced CKD?
One of the classic warnings you hear: “Stop metformin if your kidneys get weak.”
But new research from Scotland, published in the American Journal of Kidney Diseases, just turned that recommendation upside-down.
Large, nationwide target trial in stage 4 CKD (eGFR <30). Researchers compared people who continued metformin vs. those who stopped.
Those who stayed on metformin actually did better, with improved outcomes and no spike in adverse effects.
The bottom line: For people with moderate-to-advanced kidney disease, the blanket ban on metformin is being challenged. If you or someone you know has CKD, it’s time to revisit this conversation with your provider.
3. Diabetes Prevention Over 21 Years
A 2025 update from the legendary Diabetes Prevention Program Outcomes Study (DPPOS) dropped in The Lancet Diabetes & Endocrinology.
This is real long-term data:
Over 21 years of follow-up, metformin users had a 17% reduced risk of developing type 2 diabetes compared to placebo.
Onset of diabetes was delayed by an average of 2.5 years. In the aging world, every year you keep metabolic disease at bay is a year you keep your cells younger.
This is the kind of durability you never see in the supplement industry. Metformin remains the gold standard for diabetes prevention — period.
4. Metformin and COVID-19: The Long Haul
Yes, we’re still learning about COVID-19.
A new 2025 meta-analysis published in a BMJ-affiliated PubMed listing looked at metformin’s effects on acute and long-term COVID-19 outcomes.
While metformin doesn’t seem to impact acute (hospital) outcomes, it may reduce the risk of long COVID by about 40% (Relative Risk ~0.60).
This adds to a growing story of metformin’s unique ability to modulate inflammation and viral aftermath, not just blood sugar.
If you’re worried about long COVID or chronic fatigue post-infection, metformin is a tool worth discussing with your physician.
5. Osteoarthritis Pain Relief
Here’s one nobody saw coming.
A double-blind, placebo-controlled JAMA study in 2025 asked: Can metformin help with knee osteoarthritis pain, even if you don’t have diabetes?
Overweight, non-diabetic adults took metformin or placebo for 6 months.
The metformin group saw a 31-point drop (on a 0–100 scale) in knee pain — significantly more than placebo.
We know inflammation is the root of all evil, and here’s proof that metformin’s anti-inflammatory effects are showing up outside of classic metabolic disease.
6. Pediatric Fatty Liver
If you think metformin is just for aging adults, think again. A correspondence in the European Journal of Pediatrics this June reported:
Kids with metabolic-associated steatotic liver disease (MASLD) showed improved liver enzyme levels after metformin treatment.
While it’s early data, it’s fueling more trials in kids with obesity or fatty liver.
7. Brain Health: Pilot Data for Parkinson’s Disease
We’re starting to see small but exciting signals for neuroprotection.
Frontiers in Pharmacology published a pilot RCT in Parkinson’s disease:
Metformin is being explored for its anti-inflammatory and autophagy-inducing effects in the brain.
Early results support the idea that it could help slow progression or reduce symptoms.
8. Oncology, Cardio, and Beyond
A comprehensive review in the Journal of Translational Medicine details metformin’s “second act” as a multi-disease therapeutic:
Over 368 clinical trials are actively repurposing metformin in cancer, heart disease, neurology, and more.
One of the hottest topics: Ohio State is investigating metformin as a colon-cancer adjunct in KRAS-mutant cases. This is massive, as it might be able to help “starve out” some of the most stubborn tumors.
Final Thoughts
All this new data only strengthens the argument for metformin as the single most important, widely available anti-aging molecule on the market today.
Whether you’re thinking longevity, inflammation, neuroprotection, or metabolic mastery, the evidence is stacking up at an incredible rate.
If you’re ready to take action, you can get 35% off the retail price of metformin from BioLongevity Labs.
You’ll get 20% off automatically, plus an extra 15% in your cart when you use code HUNTERW at checkout.
Shop Metformin at BioLongevity Labs and unlock its benefits today.
Best,
Hunter Williams